AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier in a dosage form adapted for intranasal, transmucosal, transdermal, or intradermal administration sufficient to establish in a patient a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picograms desmopressin per mL plasma/serum and to decrease urine production, with the proviso that said dosage form does not produce a desmopressin plasma/serum concentration exceeding about 10 pg/ml.

2. (Canceled).

3. (Previously presented) The pharmaceutical composition of claim 1 comprising from about 0.05 μg to about 10 μg desmopressin.

4. (Previously presented) The pharmaceutical composition of claim 1 comprising from about 0.1 μg to about 2 μg desmopressin.

5. (Canceled)

6. (Previously presented) The pharmaceutical composition of claim 1 in a dosage form of an orodispersible solid adapted for sublingual or buccal administration.

7. (Original) The pharmaceutical composition of claim 1, further comprising an open matrix network, said open matrix network comprising a water-soluble or water-dispersible carrier material that is inert towards desmopressin.

8. (Canceled)

9. (Previously presented) The pharmaceutical composition of claim 1 in a dosage form sufficient to establishes in a patient a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per mL plasma/serum to about 5.0 picograms desmopressin per mL plasma/serum.

10-26 (Canceled).

27. (Currently amended) A pharmaceutical dosage form comprising desmopressin and a pharmaceutically acceptable carrier adapted for intranasal, transmucosal, transdermal, or intradermal administration which when administered to a patient establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picograms desmopressin per mL plasma/serum for a time between four and six hours and decreases urine production.

28. (Previously presented) The composition of claim 27 which establishes a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per mL plasma/serum to about 5.0 picograms desmopressin per mL plasma/serum.